Day One (DAWN) | Financial Analysis & Statements
Day One Biopharmaceuticals, Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
53.7M
Gross Profit
47.6M
88.68%
Operating Income
-27.5M
-51.12%
Net Income
-21.3M
-39.61%
Balance Sheet Metrics
Total Assets
507.8M
Total Liabilities
66.7M
Shareholders Equity
441.2M
Debt to Equity
0.15
Cash Flow Metrics
Operating Cash Flow
-21.1M
Free Cash Flow
-14.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Day One Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 158.2M | 131.2M | 0 | 0 | 0 |
| Cost of Goods Sold | 17.2M | 5.3M | - | - | - |
| Gross Profit | 141.0M | 125.9M | - | - | - |
| Gross Margin % | 89.1% | 96.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 148.1M | 227.7M | 130.5M | 85.6M | 43.6M |
| Selling, General & Administrative | 120.6M | 115.4M | 75.5M | 61.3M | 29.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 268.7M | 343.2M | 206.1M | 146.9M | 72.7M |
| Operating Income | -127.8M | -217.3M | -206.1M | -146.9M | -72.7M |
| Operating Margin % | -80.8% | -165.7% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 18.5M | 128.9M | 17.1M | 4.7M | -11.0K |
| Pre-tax Income | -109.3M | -88.4M | -188.9M | -142.2M | -72.8M |
| Income Tax | -2.0M | 7.1M | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -107.3M | -95.5M | -188.9M | -142.2M | -72.8M |
| Net Margin % | -67.8% | -72.8% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -142.4M | -234.9M | -222.9M | -151.1M | -72.5M |
| EPS (Basic) | - | $-1.02 | $-2.37 | $-2.17 | $-4.62 |
| EPS (Diluted) | - | $-1.02 | $-2.37 | $-2.17 | $-4.62 |
| Basic Shares Outstanding | - | 93234195 | 79773004 | 65466773 | 36960569 |
| Diluted Shares Outstanding | - | 93234195 | 79773004 | 65466773 | 36960569 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Day One Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 197.1M | 125.0M | 230.8M | 85.3M | 284.3M |
| Short-term Investments | 244.0M | 406.8M | 135.6M | 257.0M | 0 |
| Accounts Receivable | 26.7M | 13.9M | - | - | - |
| Inventory | 6.3M | 3.3M | - | - | - |
| Other Current Assets | 3.7M | 4.4M | 2.4M | 1.0M | 1.0M |
| Total Current Assets | 485.1M | 562.3M | 375.3M | 347.9M | 289.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.5M | 4.7M | 560.0K | 719.0K | 227.0K |
| Goodwill | 18.0M | 15.6M | - | - | - |
| Intangible Assets | 18.0M | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 230.0K | 121.0K | 214.0K | 469.0K | 169.0K |
| Total Non-Current Assets | 22.7M | 20.5M | 774.0K | 1.2M | 453.0K |
| Total Assets | 507.8M | 582.8M | 376.0M | 349.1M | 289.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.7M | 3.3M | 2.6M | 260.0K | 1.7M |
| Short-term Debt | 174.0K | 10.0K | 408.0K | 405.0K | 204.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 672.0K | 12.2M | 1.0M | 179.0K | 104.0K |
| Total Current Liabilities | 60.5M | 73.5M | 29.5M | 16.6M | 8.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.6M | 2.6M | 0 | 408.0K | 16.0K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 484.0K | 761.0K | - | - | - |
| Total Non-Current Liabilities | 6.1M | 6.6M | 0 | 408.0K | 16.0K |
| Total Liabilities | 66.7M | 80.0M | 29.5M | 17.0M | 8.7M |
| Equity | |||||
| Common Stock | 10.0K | 10.0K | 9.0K | 7.0K | 6.0K |
| Retained Earnings | -661.4M | -554.1M | -458.6M | -269.7M | -127.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 441.2M | 502.8M | 346.5M | 332.0M | 281.1M |
| Key Metrics | |||||
| Total Debt | 2.8M | 2.6M | 408.0K | 813.0K | 220.0K |
| Working Capital | 424.6M | 488.9M | 345.8M | 331.3M | 280.7M |
Balance Sheet Composition
Day One Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -107.3M | -95.5M | -188.9M | -142.2M | -72.8M |
| Depreciation & Amortization | 3.8M | 2.0M | 383.0K | 531.0K | 199.0K |
| Stock-Based Compensation | 44.4M | 48.3M | 39.3M | 27.2M | 13.3M |
| Working Capital Changes | -15.3M | -11.2M | 1.9M | -1.8M | 1.4M |
| Operating Cash Flow | -74.5M | -1.4M | -144.3M | -116.2M | -49.9M |
| Investing Activities | |||||
| Capital Expenditures | -288.0K | -2.2M | -224.0K | -26.0K | 0 |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -695.8M | -658.6M | -443.8M | -394.2M | 0 |
| Investment Sales | 874.2M | 393.9M | 575.4M | 139.2M | 0 |
| Investing Cash Flow | 178.1M | -266.9M | 131.4M | -255.1M | 0 |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | 178.2M | 161.4M | 161.6M | 296.8M |
| Free Cash Flow | -107.6M | -152.4M | -150.1M | -109.9M | -56.5M |
| Net Change in Cash | 103.7M | -90.1M | 148.5M | -209.7M | 246.9M |
Cash Flow Trend
Day One Key Financial Ratios
Valuation Ratios
Forward P/E
-503.04
Price to Book
5.02
Price to Sales
14.04
PEG Ratio
-503.04
Profitability Ratios
Profit Margin
-67.85%
Operating Margin
-51.12%
Return on Equity
-22.74%
Return on Assets
-14.64%
Financial Health
Current Ratio
8.02
Debt to Equity
0.63
Beta
-1.75
Per Share Data
EPS (TTM)
$-1.04
Book Value per Share
$4.28
Revenue per Share
$1.53
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DAWN | 2.2B | - | 5.02 | -22.74% | -67.85% | 0.63 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






